A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and efficacy, in terms of objective response, of CP-751,871 in this patient population

Outcome Time Frame:

20 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4021020

NCT ID:

NCT00560235

Start Date:

March 2008

Completion Date:

October 2012

Related Keywords:

• Ewing's Sarcoma Family of Tumors
• Sarcoma, Ewing's
• Neuroectodermal Tumors, Primitive, Peripheral
• Sarcoma